152 related articles for article (PubMed ID: 11295061)
21. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions.
Economidou F; Antoniou KM; Tzanakis N; Sfiridaki K; Siafakas NM; Schiza SE
Respir Med; 2008 May; 102(5):774-9. PubMed ID: 18304793
[TBL] [Abstract][Full Text] [Related]
22. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions.
Lieser EA; Croghan GA; Nevala WK; Bradshaw MJ; Markovic SN; Mansfield AS
Lung Cancer; 2013 Oct; 82(1):63-8. PubMed ID: 23948549
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma.
König JE; Tolnay E; Wiethege T; Müller KM
Virchows Arch; 1999 Jul; 435(1):8-12. PubMed ID: 10431840
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis is an independent prognostic factor in malignant mesothelioma.
Edwards JG; Cox G; Andi A; Jones JL; Walker RA; Waller DA; O'Byrne KJ
Br J Cancer; 2001 Sep; 85(6):863-8. PubMed ID: 11556838
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.
Birnie KA; Prêle CM; Musk AWB; de Klerk N; Lee YCG; Fitzgerald D; Allcock RJN; Thompson PJ; Creaney J; Badrian B; Mutsaers SE
Dis Markers; 2019; 2019():8628612. PubMed ID: 31481984
[TBL] [Abstract][Full Text] [Related]
28. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
29. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
30. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression.
Sivertsen S; Hadar R; Elloul S; Vintman L; Bedrossian C; Reich R; Davidson B
Lung Cancer; 2006 Dec; 54(3):309-17. PubMed ID: 16996643
[TBL] [Abstract][Full Text] [Related]
31. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions.
Thickett DR; Armstrong L; Millar AB
Thorax; 1999 Aug; 54(8):707-10. PubMed ID: 10413724
[TBL] [Abstract][Full Text] [Related]
34. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.
Thylén A; Hjerpe A; Martensson G
Cancer; 2001 Sep; 92(5):1224-30. PubMed ID: 11571736
[TBL] [Abstract][Full Text] [Related]
36. Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells.
Teder P; Versnel MA; Heldin P
Int J Cancer; 1996 Jul; 67(3):393-8. PubMed ID: 8707414
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8.
Antony VB; Hott JW; Godbey SW; Holm K
Chest; 1996 Mar; 109(3 Suppl):21S-22S. PubMed ID: 8598137
[No Abstract] [Full Text] [Related]
38. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.
Hamed EA; El-Noweihi AM; Mohamed AZ; Mahmoud A
Respirology; 2004 Mar; 9(1):81-6. PubMed ID: 14982607
[TBL] [Abstract][Full Text] [Related]
39. A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma.
Tabata C; Hirayama N; Tabata R; Yasumitsu A; Yamada S; Murakami A; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Terada T; Nakano T
Eur Respir J; 2010 Nov; 36(5):1099-105. PubMed ID: 20185425
[TBL] [Abstract][Full Text] [Related]
40. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
